Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, Jianjun, Shi, Lewis Zhichang, Zhao, Hao, Chen, Jianfeng, Xiong, Liangwen, He, Qiuming, Chen, Tenghui, Roszik, Jason +8 more·2016·Cell

DOI 10.1016/j.cell.2016.08.069

Cited by (1,000)

Items 301–400 of 1,000

Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations
Masashi Fujita, Rui Yamaguchi, Takanori Hasegawa, Shu Shimada, Koji Arihiro, Shuto Hayashi, Kazuhiro Maejima, Kaoru Nakano, Akihiro Fujimoto, Atsushi Ono et al. · 2020 · EBioMedicine
Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression
Nicolas Curdy, Olivia Lanvin, Camille Laurent, Jean‐Jacques Fournié, Don‐Marc Franchini · 2019 · Trends in Cell Biology
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Bonnie L. Russell, Selisha Ann Sooklal, Sibusiso Tebogo Malindisa, Lembelani Jonathan Daka, Monde McMillan Ntwasa · 2021 · Frontiers in Oncology
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker Martin Lauschke, Isabel Barragán · 2020 · Journal of Clinical Medicine
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
Wantao Wu, Yihan Liu, Shan Zeng, Ying Han, Hong Shen · 2021 · Journal of Hematology & Oncology
Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ–stimulated antitumor immunity
Jiale Ren, Ni Li, Siyu Pei, Yannan Lian, Li Li, Yuchong Peng, Qiuli Liu, Jiacheng Guo, Xuege Wang, Ying Han et al. · 2022 · Journal of Clinical Investigation
Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
Yefang Lao, Daoming Shen, Weili Zhang, Rui He, Min Jiang · 2022 · Cancers
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Michal Šmahel · 2017 · International Journal of Molecular Sciences
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
Yared Hailemichael, Amber N. Woods, Tihui Fu, Qiuming He, Michael C. Nielsen, Farah Hasan, Jason Roszik, Zhilan Xiao, Christina Vianden, Hiep Khong et al. · 2018 · Journal of Clinical Investigation
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Xiaolei Li, Wenhui Song, Changshun Shao, Yufang Shi, Weidong Han · 2018 · Cellular and Molecular Immunology
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Hongxing Shen, Eddy Shih-Hsin Yang, M. Conry, John B. Fiveash, Carlo M. Contreras, James A. Bonner, Lewis Z. Shi · 2019 · Genes & Diseases
Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
Binghan Zhou, Yuan Gao, Peng Zhang, Qian Chu · 2021 · Frontiers in Immunology
HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells
Hongxing Shen, Oluwagbemiga A. Ojo, Haitao Ding, Logan J. Mullen, Chuan Xing, Mohammed Iqbal Hossain, Abdelrahman Yassin, Vivian Yan Shi, Zach Lewis, Ewa Podgórska et al. · 2024 · Nature Communications
Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity
Dapeng Hao, Jie Liu, Meng Chen, Jingjing Li, Li Wang, Xiaobo Li, Qi Zhao, Lijun Di · 2018 · Clinical Cancer Research
Emerging Role of Extracellular Vesicles in Immune Regulation and Cancer Progression
Sonam Mittal, Prachi Gupta, Pradeep Chaluvally–Raghavan, Sunila Pradeep · 2020 · Cancers
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy
Sujing Yuan, Renqiang Sun, Hao Shi, Nicole M. Chapman, Haoran Hu, Cliff S. Guy, Sherri L. Rankin, Anil KC, Gustavo Palacios, Xiaoxi Meng et al. · 2025 · Nature
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
Cécile Gstalder, David Liu, Diana Miao, Bart A. Lutterbach, Alexander L. DeVine, Chenyu Lin, Megha Shettigar, Priya Pancholi, Elizabeth Iannotti Buchbinder, Scott L. Carter et al. · 2020 · Cancer Discovery
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Suying Yan, Wanting Wang, Zhiqiang Feng, Jun Xue, Weizheng Liang, Xueliang Wu, Zhiquan Tan, Xipeng Zhang, Shuai Zhang, Xichuan Li et al. · 2024 · Frontiers in Immunology
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Chunxiao Xu, Yanping Zhang, Alex Rolfe, Vivian M. Hernández, Wilson Guzman, Giorgio Kradjian, Bo Marelli, Guozhong Qin, Jin Qi, Hong Wang et al. · 2017 · Clinical Cancer Research
The evolutionary legacy of immune checkpoint inhibitors
Kaushik, Itishree, Ramachandran, Sharavan, Zabel, Carson, Gaikwad, Shreyas, Srivastava, Sanjay K. · 2022 · Seminars in Cancer Biology
Role of Type I and II Interferons in Colorectal Cancer and Melanoma
Simone Di Franco, Alice Turdo, Matilde Todaro, Giorgio Stassi · 2017 · Frontiers in Immunology
Identification of non-mutated neoantigens presented by TAP-deficient tumors
Koen A. Marijt, Laura Blijleven, Els M.E. Verdegaal, Michel G.D. Kester, Daniel Johannes Kowalewski, Hans‐Georg Rammensee, Stefan Stevanović, Mirjam H.M. Heemskerk, Sjoerd H. van der Burg, Thorbald van Hall · 2018 · The Journal of Experimental Medicine
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
Kartik Sehgal, Andrew J. Portell, Elena V. Ivanova, Patrick Hall Lizotte, Navin R. Mahadevan, Jonathan R. Greene, Amir Vajdi, Carino Gurjao, Tyler J. Teceno, Luke J. Taus et al. · 2020 · Journal of Clinical Investigation
ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance
Li Jiang, Yajing Hao, Changwei Shao, Qiulian Wu, Briana C. Prager, Ryan C. Gimple, Gabriele Sulli, Leo J.Y. Kim, Guoxin Zhang, Zhixin Qiu et al. · 2022 · Journal of Clinical Investigation
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression
Rikke Sick Andersen, Troels Holz Borch, Arianna Draghi, Aishwarya Gokuldass, M.A.H. Rana, Magnus Pedersen, Morten Nielsen, Per Kongsted, Julie Westerlin Kjeldsen, Marie Christine Wulff Westergaard et al. · 2018 · Annals of Oncology
Future Challenges in Cancer Resistance to Immunotherapy
Marit J van Elsas, Thorbald van Hall, Sjoerd H. van der Burg · 2020 · Cancers
Escape from T-cell–targeting immunotherapies in acute myeloid leukemia
Jayakumar Narayanan Vadakekolathu, Sergio Rutella · 2023 · Blood
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Brandie C. Taylor, Xiaopeng Sun, Paula I. González Ericsson, Violeta M. Sanchez, Melinda E. Sanders, Elizabeth C. Wescott, Susan R. Opalenik, Ann Hanna, Shu-Ting Chou, Luc Van Kaer et al. · 2023 · Cancer Discovery
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
Maria Carmela Speranza, Carmela Passaro, Franz Lennard Ricklefs, Kazue Kasai, Sarah R. Klein, Hiroshi Nakashima, Johanna K. Kaufmann, Abdul-Kareem Ahmed, Michal Oskar Nowicki, Prisca Obi et al. · 2017 · Neuro-Oncology
Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints
Diana Saleiro, Leonidas C. Platanias · 2019 · Seminars in Immunology
Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
Ines Malenica, Julien Adam, Stéphanie Corgnac, Laura Mezquita, Édouard Auclin, Isabelle Damei, Laetitia Grynszpan, Gwendoline Gros, Vincent de Montpréville, David Planchard et al. · 2021 · Nature Communications
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
Xiulei Mo, Qiankun Niu, Andrei A. Ivanov, Yiu Huen Tsang, Cong Tang, Changfa Shu, Qianjin Li, Kun Qian, Alafate Wahafu, Sean P. Doyle et al. · 2022 · Cell
The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors
Melissa Tian Bu, Pallavi Chandrasekhar, Lizhong Ding, Willy Hugo · 2022 · Pharmacology & Therapeutics
Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial Carcinoma
Ryan Dz-Wei Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich, Elena Bonazzoli, Akiko Iwasaki, Eric Song, Alessandro Davide Santin · 2022 · Cancer Discovery
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Jeffrey S. Weber, Mario Sznol, Ryan Joseph Sullivan, Shauna M. Blackmon, Genevieve Marie Boland, Harriet M. Kluger, Ruth Halaban, Antonietta Bacchiocchi, Paolo A. Ascierto, Mariaelena Capone et al. · 2017 · Cancer Immunology Research
PD‐1 Blockade for Improving the Antitumor Efficiency of Polymer–Doxorubicin Nanoprodrug
Fan Gao, Chi Zhang, Wen‐Xiu Qiu, Xue Dong, Diwei Zheng, Wei Hong Wu, Xian‐Zheng Zhang · 2018 · Small
Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response–related genes
Ke-Yue Ma, Alexandra A. Schonnesen, Amy Brock, Carla Van Den Berg, S. Gail Eckhardt, Zhihua Liu, Ning Jenny Jiang · 2019 · JCI Insight
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
Francesco Sabbatino, Antonio Marra, Luigi Liguori, Giosuè Scognamiglio, Celeste Fusciello, Gerardo Botti, Soldano Ferrone, Stefano Pepe · 2018 · Journal for ImmunoTherapy of Cancer
Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination
Éléonore De Guillebon, Antoine Dardenne, Antonin Saldmann, Sylvie Séguier, Thi Tran, Léa Paolini, Célèste Lebbé, Éric Tartour · 2020 · International Journal of Cancer
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers
Jan David Beck, Mustafa Diken, M Suchan, Michael Streuber, Elif Diken, LAURA D. KOLB, Lisa Allnoch, Fulvia Vascotto, Daniel Peters, Tim Beißert et al. · 2024 · Cancer Cell
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade
Nivine Srour, Oscar David Villarreal, Swanand Hardikar, Zhenbao Yu, Samuel E.J. Preston, Wilson H. Miller, Magdelena M. Szewczyk, Dalia Baršytė-Lovejoy, Han Xu, Taiping Chen et al. · 2022 · Cell Reports
Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy
Yu Dong, Qian Gao, Yong Chen, Zhao Zhang, Yanhua Du, Yuan Liu, Guangxiong Zhang, Shengli Li, Gaoyang Wang, Xiang Chen et al. · 2023 · Nature Communications
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
Kristin C. Hicks, Massimo Claudio Fantini, Renee Nicole Donahue, Angie Schwab, Karin M. Knudson, Sarah Renee Tritsch, Caroline Jochéms, Paúl E. Clavijo, Clint Tanner Allen, James W. Hodge et al. · 2018 · OncoImmunology
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
Haizhou Wang, Yabo Zhou, Yangyang Zhang, Shilin Fang, Meng Zhang, Haiou Li, Fei Xu, Lan Liu, Jing Liu, Qiu Zhao et al. · 2022 · Journal for ImmunoTherapy of Cancer
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
Hsiang‐Fong Kao, Bin-Chi Liao, Yenlin Huang, Huai‐Cheng Huang, Chun‐Nan Chen, Tseng‐Cheng Chen, Yuan-Jing Hong, Ching-Yi Chan, Jean‐San Chia, Ruey‐Long Hong · 2022 · Clinical Cancer Research
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
Marc C. Pulanco, Anne Tranberg Madsen, Ankit Tanwar, Devin T. Corrigan, Xingxing Zang · 2023 · Cellular and Molecular Immunology
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype
Ashvin R. Jaiswal, Arthur J. Liu, Shivanand Pudakalakatti, Prasanta Dutta, Priyamvada Jayaprakash, Todd Bartkowiak, Casey R. Ager, Zhiqiang Wang, Alexandre Reuben, Zachary Aaron Cooper et al. · 2020 · Cancer Immunology Research
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Rachael M. Zemek, Wee Loong Chin, Anna K. Nowak, Michael Millward, Richard Lake, Willem Joost Lesterhuis · 2020 · Frontiers in Immunology
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
A. Ari Hakimi, Kyrollis Attalla, Renzo G. DiNatale, Irina Ostrovnaya, Jessica R. Flynn, Kyle A. Blum, Yasser M. A. Ged, Douglas Robert Hoen, Sviatoslav M. Kendall, Ed Reznik et al. · 2020 · Nature Communications
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Elena Shklovskaya, Helen Rizos · 2021 · International Journal of Molecular Sciences
Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
Pinhao Fang, Jianfeng Zhou, Zhiwen Liang, Yu‐Shang Yang, Siyuan Luan, Xin Xiao, Xiaokun Li, Hanlu Zhang, Qixin Shang, Xiaoxi Zeng et al. · 2022 · Frontiers in Immunology
Co-Signaling Molecules in Maternal–Fetal Immunity
Yuanyuan Xu, Songcun Wang, Da‐Jin Li, Meirong Du · 2016 · Trends in Molecular Medicine
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance
Donjeta Gjuka, Elio Adib, Kendra Garrison, Jianfeng Chen, Yuxue Zhang, Wenjiao Li, Daniel R. Boutz, Candice Lamb, Yuri Tanno, Amin H. Nassar et al. · 2023 · Cancer Cell
Biomimetic Nanovehicle-Enabled Targeted Depletion of Intratumoral Fusobacterium nucleatum Synergizes with PD-L1 Blockade against Breast Cancer
Shizhen Geng, Pengke Guo, Xinling Li, Yaru Shi, Jing Wang, Mengnian Cao, Yunya Zhang, Kaixiang Zhang, Airong Li, Haiwei Song et al. · 2024 · ACS Nano
Drug Resistance in Cancer Therapy and the Role of Epigenetics
Takeshi Asano · 2020 · Journal of Nippon Medical School
FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer
Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri · 2021 · Cancers
Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3
Young Min Chung, Pragya P Khan, Hong Wang, Wen-Bin Tsai, Yanli Qiao, Bo Yu, James W. Larrick, Mickey C.‐T. Hu · 2021 · Journal for ImmunoTherapy of Cancer
Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers
Satoshi Muto, Akio Enta, Yoshiyuki Maruya, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue et al. · 2023 · Biomedicines
Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment
Javed Mahmood, Hem Dutt Shukla, Sandrine Soman, Santanu Samanta, Prerna Singh, Shriya Kamlapurkar, Ali M. Saeed, Neha P. Amin, Željko Vujašković · 2018 · Cancers
Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response
Asier Antoranz, Yannick Van Herck, Maddalena M. Bolognesi, Seodhna M. Lynch, Arman Rahman, William M. Gallagher, Veerle Boecxstaens, Jean‐Christophe Marine, Giorgio Cattoretti, Joost J. van den Oord et al. · 2022 · Cancer Research
Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
Yiwen Zheng, Shujin Li, Hongchao Tang, Xuli Meng, Qinghui Zheng · 2023 · Frontiers in Immunology
Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming
Ting Yu, Zhaoyun Liu, Qingxu Tao, XianRui Xu, Xinyang Li, Yang Li, Minxin Chen, Rufei Liu, Dawei Chen, Meng Wu et al. · 2024 · Cancer Letters
Treatment resistance in urothelial carcinoma: an evolutionary perspective
Panagiotis J. Vlachostergios, Bishoy M. Faltas · 2018 · Nature Reviews Clinical Oncology
Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways
Kaijian Zhou, Shu Guo, Shuang Tong, Qiang Sun, Fei Li, Xiaowei Zhang, Ying Qiao, Guoxin Liang · 2018 · Stem Cells and Development
Immune signatures correlate with L1 retrotransposition in gastrointestinal cancers
Hyunchul Jung, Jung Kyoon Choi, Eunjung Alice Lee · 2018 · Genome Research
Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
Feng Xie, Jianjun J. Zhang, Jiayin Wang, Alexandre Reuben, Wei Xu, Xin Yi, Frederick S. Varn, Yongsheng Ye, Junwen Cheng, Miao Yu et al. · 2020 · Clinical Cancer Research
Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex–mediated STAT1 downregulation
Xiaoyan Zhan, Saisai Guo, Yuanyuan Li, Haowen Ran, Haohao Huang, Lanjuan Mi, Jin Wu, Xinzheng Wang, Dake Xiao, Lishu Chen et al. · 2020 · The Journal of Experimental Medicine
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy
Lina Such, Fang Zhao, Derek H. Liu, Beatrice Thier, Vu Thuy Khanh Le‐Trilling, Antje Sucker, Christoph Coch, Natalia Pieper, Sebastian Howe, Hilal Bhat et al. · 2020 · Journal of Clinical Investigation
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas
Yinglu Li, Elizabeth M. Goldberg, Xiao Chen, Xinjing Xu, John T. McGuire, Giuseppe Leuzzi, Dimitris Karagiannis, Tiffany Tate, Nargess Farhangdoost, Cynthia Horth et al. · 2022 · Molecular Cell
FOXP3+ regulatory T cell perturbation mediated by the IFNγ-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity
Xinnan Liu, Weiqi Zhang, Yichao Han, Hao Cheng, Qi Liu, Shouyu Ke, Fangming Zhu, Ying Chun Lu, Xin Dai, Chuan Wang et al. · 2024 · Nature Communications
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy
Daniel Davies, Shraddha Kamdar, Richard Woolf, Iva Zlatareva, Maria Luisa Iannitto, Cienne Morton, Yasmin Haque, Hannah Martin, Dhruva Biswas, Susan Ndagire et al. · 2024 · Nature Cancer
Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
Floris F. Dammeijer, Sai Ping Lau, Casper H.J. van Eijck, Sjoerd H. van der Burg, Joachim G.J.V. Aerts · 2017 · Cytokine & Growth Factor Reviews
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Claire Lhuillier, Claire Vanpouille‐Box, Lorenzo Galluzzi, Silvia Chiara Formenti, Sandra Demaria · 2017 · Seminars in Cancer Biology
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort
Kyle Gregory Mitchell, Lixia Diao, Tatiana V. Karpinets, Marcelo Vailati Negrao, Hai Thanh Tran, Edwin Roger Parra, Erin M. Corsini, Alexandre Reuben, Lorenzo Federico, Chantale Bernatchez et al. · 2020 · Journal for ImmunoTherapy of Cancer
Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Alex M. Jaeger, Lauren E. Stopfer, Sunmin Lee, Giorgio Gaglia, Demi A. Sandel, Sandro Santagata, NU Lin, Jane B. Trepel, Forest M. White, Tyler Jacks et al. · 2019 · Clinical Cancer Research
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
Yu Fujiwara, Arjun Mittra, Abdul Rafeh Naqash, Naoko Takebe · 2020 · Cancer Drug Resistance
SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 Axis
Satoru Yokoyama, Atsushi Takahashi, Ryota Kikuchi, Soshi Nishibu, Jennifer A. Lo, Miroslav Hejna, Wooyoung M. Moon, Shinichiro Kato, Yue Zhou, Frank Stephen Hodi et al. · 2021 · Cancer Research
Cellular heterogeneity in TNF/TNFR1 signalling: live cell imaging of cell fate decisions in single cells
Marcus K Preedy, Michael White, Vinay Tergaonkar · 2024 · Cell Death and Disease
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
Nicholas C. Borcherding, Ryan H. Kolb, Jodi A. Gullicksrud, Praveen Vikas, Yuwen Zhu, Weizhou Zhang · 2018 · Journal of Molecular Biology
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
Kwoneel Kim, Hong Sook Kim, Jeong Yeon Kim, Hyunchul Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Se‐Hoon Lee, Jung Kyoon Choi · 2020 · Nature Communications
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Robert Ballotti, Yann Chéli, Corine Bertolotto · 2020 · Molecular Cancer
Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities
Davood Bashash, Zahra Zandi, Bahareh Kashani, Atieh Pourbagheri‐Sigaroodi, Sina Salari, Seyed Hamidollah Ghaffari · 2021 · Journal of Cellular Physiology
Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Zhenqing Ye, Haidong Dong, Ying Li, Tao Ma, Haojie Huang, Hon Sing Leong, Jeanette E. Eckel‐Passow, Jean‐Pierre Kocher, Han Liang, Liguo Wang · 2018 · Clinical Cancer Research
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Jean Lemoine, Marco Ruella, Roch Houot · 2021 · Clinical Cancer Research
The complex role of AIM2 in autoimmune diseases and cancers
Huan Zhu, Ming Zhao, Christopher Chia-Chi Chang, Vera S. F. Chan, Qianjin Lu, Haijing Wu · 2021 · Immunity Inflammation and Disease
Molecular predictors of response to pembrolizumab in thymic carcinoma
Yongfeng He, Archana Ramesh, Yuriy Gusev, Krithika Bhuvaneshwar, Giuseppe Giaccone · 2021 · Cell Reports Medicine
Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy
Sajad Fakhri, Seyed Zachariah Moradi, Akram Yarmohammadi, Fatemeh Narimani, Carly E. Wallace, Anupam Bishayee · 2022 · Frontiers in Oncology
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
Georgi Apriamashvili, David W. Vredevoogd, Oscar Krijgsman, Onno B. Bleijerveld, Maarten Alexander Ligtenberg, Beaunelle de Bruijn, Julia Boshuizen, Joleen J.H. Traets, Daniela M. D'Empaire Altimari, Alex v. Vliet et al. · 2022 · Nature Communications
Biomarkers for immunotherapy for treatment of glioblastoma
John P. Lynes, Anthony Nwankwo, Hannah P. Sur, Victoria E Sanchez, Kwadwo Sarpong, Oluwatobi Ariyo, Gifty A. Dominah, Edjah Kweku-Ebura Nduom · 2020 · Journal for ImmunoTherapy of Cancer
Emerging biomarkers for cancer immunotherapy in melanoma
Margaret L. Axelrod, Douglas Buckner Johnson, Justin Micah Balko · 2017 · Seminars in Cancer Biology
Chemical and genetic control of IFNγ‐induced MHCII expression
Ruud H. M. Wijdeven, Marvin M. van Luijn, Annet F. Wierenga‐Wolf, Jimmy J.L.L. Akkermans, Peter J. van den Elsen, Rogier Q. Hintzen, Jacques Neefjes · 2018 · EMBO Reports
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2
Pengfei Xu, Shuangyan Ye, Keyi Li, Mengqiu Huang, Qianli Wang, Sisi Zeng, Xi Chen, Wenwen Gao, Jianping Chen, Qianbing Zhang et al. · 2019 · Journal of Experimental & Clinical Cancer Research
Cancer neoantigens as potential targets for immunotherapy
Weijie Ma, Brian Pham, Tianhong Li · 2021 · Clinical & Experimental Metastasis
The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies
Danting Wang, Qizhen Ye, Haochen Gu, Zhigang Chen · 2022 · Frontiers in Oncology
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response
Meghana S. Pagadala, Timothy J. Sears, Victoria H. Wu, Eva Pérez‐Guijarro, Hyo Kim, Andrea Castro, James V. Talwar, Cristian González-Colín, Steven Cao, Benjamin Joachim Schmiedel et al. · 2023 · Nature Communications
RNA vaccines for cancer: Principles to practice
Pablo Guasp, Charlotte Reiche, Zachary M. Sethna, Vinod P. Balachandran · 2024 · Cancer Cell
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Saud Almawash · 2025 · Cancers
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Yvette L. Robbins, Sarah Greene, Jay Friedman, Paúl E. Clavijo, Carter Van Waes, Kellsye P. Fabian, Michelle R. Padget, Houssein Abdul Sater, John H Lee, Patrick Soon‐Shiong et al. · 2020 · eLife
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Juan Ruiz Bañobre, Ajay Goel · 2018 · Gastroenterology